Tests surovatamig in adults with returned B-cell non-Hodgkin lymphoma
Tests surovatamig alone in adults whose B-cell lymphoma has returned or not responded.
Plain-language title generated from the registry record
Registry title: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Key facts
- Where
- Heidelberg, Kogarah, Macquarie University, and Nedlands, AustraliaSee the 4 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose follicular lymphoma or large B-cell lymphoma came back or did not respond after at least 2 earlier treatments. All get surovatamig (AZD0486).
- Age
- 18 years and older
- Sex
- Men and women can join
- Disease stage
- Follicular lymphoma (Module 1) or large B-cell lymphoma (Module 2) that came back or did not respond after at least 2 prior lines of therapy. Disease must show on a scan (FDG-avid) with at least one measurable lesion.
- Earlier treatment
- At least 2 prior lines of therapy. Cannot join: T-cell engager within 8 weeks, autologous stem cell transplant within 12 weeks, CAR T-cell therapy within 6 months, or allogeneic stem cell transplant within 24 weeks before the first dose.
- Biomarker or test result
- CD-19 present in the lymphoma cells, confirmed locally after progression from the last CD 19 directed therapy.
Main reasons for not taking part
- Chronic lymphocytic leukemia (CLL), Burkitt lymphoma or Richter's transformation
- Active lymphoma in the brain or spinal fluid (CNS), or leukemic form of the lymphoma
- Serious brain or nerve condition, such as epilepsy, stroke, dementia or Parkinson's disease
- Need for long-term immune-suppressing treatment
- Pregnant or breastfeeding
Read by machine on 10 November 2026.
Where in Australia
- HeidelbergHospital not named in the registryTaking people
- KogarahHospital not named in the registryTaking people
- Macquarie UniversityHospital not named in the registryTaking people
- NedlandsHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06526793EU 2023-505789-27-00
- Record updated
- 14 October 2026
- Original description
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.Read full original descriptionShow less
A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.
Key Inclusion Criteria:; Aged 18 years old and above; Histologically confirmed relapsed refractory FL (Module 1) and LBCL (Module 2) after at least 2 prior lines of therapy; ECOG performance status 0 to 2; Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy; FDG-avid disease with at least one bi-dimensionally measurable nodal lesion (defined as > 1.5 cm in its longest dimension), or extranodal lesion (defined as > 1.0 cm in its longest dimension); Adequate hematological function: ANC ≥ 1000/mm3, platelets; 75,000/mm3, hemoglobin ≥ 9 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening; Adequate liver function: total bilirubin <1.5x ULN, AST/ALT ≤ 3xULN or < 5 × ULN in the presence of lymphoma involvement of the liver; Adequate renal function: creatinine clearance (CrCl) of ≥ 45 mL/min; Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) ≥ 45% by echocardiogram or MUGA; The above is a summary, other inclusion criteria details may apply; Key Exclusion Criteria:; Diagnosis of CLL, Burkitt lymphoma, or Richter's transformation; Active CNS involvement by B-NHL; Leukemic presentation of B-NHL; History of a clinically relevant CNS medical condition or pathology that required treatment in the preceding year, is currently symptomatic, or that the treating investigator considers to have the potential to interfere with the evaluation of safety, such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, neurodegenerative disorder including Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis or other severe mental illness; Prior therapy with T-cell engager (TCE) within 8 weeks, autologous Hematopoietic Stem Cell Transplantation (HSCT) within 12 weeks, CAR T- cell therapy within 6 months, or prior allogeneic HSCT within 24 weeks of first dose of surovatamig; Requires chronic immunosuppressive therapy; Unresolved non hematological AEs ≥ Grade 2 from prior therapies; history of ≥ Grade 3 CRS or neurotoxicity from prior CAR-T or TCE therapy; History of major cardiac abnormalities; If female, participant must not be pregnant or breastfeeding; The above is a summary, other exclusion criteria details may apply.